AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01057329 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Description: 5 mg from week 1, 10 mg from week 2
Study NCT03167372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Litebook® Advantage
Description: Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
Study NCT03167372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Litebook® Advantage
Description: Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
Study NCT03167372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Flex2 TM
Description: Standard system activity and sleep tracker
Study NCT03167372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Flex2 TM
Description: Standard system activity and sleep tracker
Study NCT03268447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum P8
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
Study NCT03268447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
Study NCT03896152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: approximately 2 year of Treatment with LNP023
Study NCT00615745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
Description: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
Study NCT02134418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT of irony comprehension
Description: Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
Study NCT03929445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube introducers
Description: Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie.
Study NCT02141620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
Study NCT02141620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
Study NCT02141620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-Acetylcysteine
Study NCT02141620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03183219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery or IRE surgery
Description: Cryosurgery or IRE surgery will be used in local tumor
Study NCT03183219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cell
Description: γδ T cells will be used against Liver Cancer
Study NCT03183219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: γδ T cells/ A Cryosurgery or IRE
Description: Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
Study NCT01505777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 15/mosapride 15mg three times a day, P.O. 4week
Study NCT00281515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Study NCT00281515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lonafarnib
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Study NCT02478268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
Study NCT02478268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
Study NCT00741364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 (cholecalciferol)
Description: liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
Study NCT02839525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3
Description: 3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
Study NCT02839525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolate whey protein
Description: 23g of protein of whey protein
Study NCT02839525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 and Isolate whey protein
Description: 3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
Study NCT02839525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
Study NCT01767571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 125 mg/5ml
Description: Reference product 20 ml
Study NCT01767571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin 250mg/5ml
Description: Test product 10 ml
Study NCT03024905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village meeting and travel vouchers
Description: The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery.
Study NCT03024905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Birth kit with misoprostol
Description: Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
Study NCT02708563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate intubation
Description: Infants that are not vigorous at delivery will receive immediate tracheal suctioning
Study NCT02708563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate resuscitation
Description: Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
Study NCT02855697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg taken twice daily, equivalent to a total daily dose of 600 mg
Study NCT02855697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 20mg dose of cediranib was selected for this study
Study NCT02855697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: 1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
Study NCT04916093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: Galvus 50 mg oral tablets
Study NCT04916093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Januvia 100mg oral tablets
Study NCT04916093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 1000 Mg Oral Tablet
Description: Glucophage 1000 mg oral tablets
Study NCT03028727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scaling and root planing
Description: Procedure of scaling and root planing at day 0 and at 1 week
Study NCT03028727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic Scaling and root planing
Description: Procedure of scaling and root planing at day 0 and at 1 week
Study NCT01505777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics (Medirac)
Description: 30/mosapride 15mg three times a day, P.O. 4week
Study NCT03028727 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 980 nm diode laser irradiation
Description: Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
Study NCT04193436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 25 mg
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1
Study NCT00620295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
Study NCT00620295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.
Study NCT05499845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: butanol threshold test and smell identification tests
Description: no additional intervention
Study NCT01505777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics (Medirac) placebo/mosapride placebo
Description: three times a day, P.O. 4week
Study NCT02594319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Study NCT02594319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring
Study NCT02404727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cup fixation
Description: All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
Study NCT02404727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avantage® Cup
Study NCT00964886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
Study NCT00964886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desipramine hydrochloride
Description: desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
Study NCT00964886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: benztropine mesylate 0.125 mg daily
Description: benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
Study NCT03775434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: B244
Description: B244 suspension in 30ml/bottle
Study NCT02594319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring
Study NCT04394598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendrobium Huoshanense Granules
Description: 3g tid per day for 5weeks
Study NCT05052177 — intervention group
Intervention type: DEVICE
Intervention: Edge to edge repair in systemic tricuspid valve regurgitation
Description: Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
Study NCT04394598 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic Radiation
Description: 50Gy/25Fx
Study NCT01828632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Physical Therapy
Description: Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
Study NCT01603134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg tablet once a day
Study NCT01603134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 300 mg tablet once a day
Study NCT04394598 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Pelvic Radiation
Description: 50Gy/25Fx
Study NCT04394598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week
Study NCT01783964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Elacytarabine
Description: Single intravenous administration
Study NCT03231280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SB-061
Description: delivered via intra-articular injection
Study NCT03231280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered via intra-articular injection
Study NCT01341054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with Chamomilla
Description: The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
Study NCT01341054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral care protocol
Description: The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
Study NCT03282825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle.
Study NCT03282825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle.
Study NCT01854398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP group
Description: Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
Study NCT01854398 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-CPAP group
Description: Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
Study NCT02405728 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centrally inserted central catheters (CICCs)
Description: Randomization between two well established clinical routine vascular access devices
Study NCT02405728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Description: Randomization between two well established clinical routine vascular access devices
Study NCT03847792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group DB/Dexamethasone-Bupivacaine
Description: The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
Study NCT03847792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group FB /Fentanyl-Bupivacaine
Description: The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
Study NCT03847792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group PB/Placebo-Bupivacaine
Description: Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
Study NCT00652327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
Description: ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
Study NCT00652327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double Statin (simvastatin, atorvastatin, or pravastatin)
Description: simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
Study NCT04767243 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Study NCT04767243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement and filled with Bioactive glass (Perioglas®)
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Study NCT04767243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Study NCT04677634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ISOThrive Prebiotic Nectar
Description: The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
Study NCT04394598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week
Study NCT04394598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
Study NCT04394598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)